Date: 2014-09-16
Type of information: Grant
Company: Inventiva (France) Curie-Cancer (France)
Investors: ANR - French National Research Agency (France)
Amount:
Funding type: grant
Planned used: The Epicure project focuses on two novel epigenetic targets implicated in immunomodulation. It aims to confirm their therapeutic potential for the treatment of cancers such as breast cancer, ovarian cancer and melanoma, as well as some respiratory diseases. It also aims to identify molecules that are capable of regulating the activity of the targets and are therefore likely to become active drugs for the treatment of these diseases.
The project will involve three teams from the Institut Curie: the Epigenetics team led by Geneviève Almouzni, director of research at the French national center for scientific research the CNRS [Centre national de recherche scientifique], and director of the research center at the Institut Curie, the Immunology team headed by Sebastian Amigorena, director of research at the CNRS, and Sergio Roman-Roman’s Translational Research team. Inventiva’s epigenetics drug discovery team will join and partner with Curie teams. The purpose of the Epicure project is to produce novel molecules that modulate the epigenetic targets under evaluation. These would be ready to go into clinical development upon completion of the project. Its ultimate goal is to find new drugs that will activate immune responses against cancer cells.
Others: * On September 16, 2014, Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR [Agence Nationale pour la Recherche]. “The ANR funding provides additional resources for the partnership we have established with the Institut Curie. It adds to our portfolio of epigenetic programs, which aims to confirm novel epigenetic mechanisms and develop innovative drugs to treat cancer,” said Pierre Broqua, co-founder and scientific director of Inventiva. The funding provided by the ANR covers a period of four years.
Therapeutic area: Cancer - Oncology - Respiratory diseases
